原能生物近日宣布，正式启动B轮融资，并积极筹备科创板上市计划。深耕自动化低温存储领域近八 年，原能生物持续攻克技术难关，推出了一系列具有自主知识产权的智能化生物样本库产品。截至2024 年12月，原能生物累计申请国内外专利600余项，获得500余个授权。 深耕国内布局全球 近年来，原能生物陆续推出覆盖全温区、全场景的BSN、P、AM、IVF、PBM、BSE等系列产品矩阵。 据公司介绍，在中国疾控、浙江疾控、苏州疾控、仁济医院、芙蓉实验室等多个项目中，原能生物的自 动化设备均成功落地；公司农林畜牧标杆案例也已落地。 "令人振奋的是，我们已经完成了从0到1的研发突破，推出了一系列全自动深低温生物样本存储设备， 接下来我们要进入1到10的高速发展阶段，我们将推动产业升级，以自动化、智能化解决方案变革传统 低效、高风险的样本管理模式，为生物医药研发、精准医疗、细胞治疗等前沿领域提供坚实可靠的设备 支撑。"瞿建国告诉记者。 "目前我们处在小批量制造的阶段，在这一过程中，我们力求把产品标准化模块化，也就是说把每一个 系列的产品做好做精，以便未来能够按照标准批量制造，降低生产成本。"瞿建国表示，从市场的角度 看，原能生物深 ...

Core Viewpoint - Yuaneng Bio has officially launched its Series B financing and is actively preparing for its listing on the Sci-Tech Innovation Board, focusing on the automation of low-temperature storage technology in the biopharmaceutical sector [1][6]. Group 1: Company Overview - Yuaneng Bio has been dedicated to the research and development of advanced automated low-temperature storage equipment for nearly eight years, with an investment of approximately 800 million yuan [3][6]. - The company has applied for over 600 domestic and international patents, with more than 500 granted [1][3]. - The company aims to transform low-temperature storage technology from laboratory applications to industrialization, driven by policy, capital, and entrepreneurial efforts [1][6]. Group 2: Product Development - Yuaneng Bio has developed a series of automated deep low-temperature biological sample storage products, including the BSN, P, AM, IVF, PBM, and BSE series [3][4]. - The company has achieved breakthroughs in technology, such as the innovative "honeycomb" storage structure that prevents cross-contamination and maintains a stable low-oxygen, frost-free environment [3][4]. - The Orcella duo1100S automated deep low-temperature storage system won the "2025 Outstanding New Product Award" at the ISBER awards in Canada [4]. Group 3: Market Strategy - The company is focusing on standardizing and modularizing its products to facilitate future mass production and reduce costs [4][6]. - Yuaneng Bio is expanding its market presence domestically while also strengthening collaborations with global partners to reach overseas customers [4][6]. - The company is targeting various application scenarios, including hospitals, disease control centers, biopharmaceutical companies, and animal research centers, as well as exploring the potential of home-based cell storage solutions [6][7]. Group 4: Future Plans - Yuaneng Bio is set to complete the construction of a smart manufacturing base in Shanghai in 2024, covering nearly 10,000 square meters [6]. - Following a successful Series A financing of 410 million yuan in 2022, the company is now preparing for its Series B financing and plans to list on the Sci-Tech Innovation Board [6][7]. - The primary use of future funds will be for factory construction and to promote the mass production of low-temperature storage equipment [6].

Core Viewpoint - Yuaneng Bio has officially launched its Series B financing and is actively preparing for its listing on the Sci-Tech Innovation Board, focusing on the automation of low-temperature storage technology for nearly eight years [1][5]. Group 1: Company Development and Innovations - The company has applied for over 600 domestic and international patents, with more than 500 granted as of December 2024 [1]. - Yuaneng Bio aims to innovate and industrialize low-temperature storage technology, moving from laboratory applications to broader industrial use, driven by policy, capital, and entrepreneurial efforts [1][5]. - The company has invested nearly 800 million yuan in the development of advanced automated low-temperature storage equipment [2]. Group 2: Product and Market Strategy - Yuaneng Bio has developed a series of automated deep low-temperature biological sample storage devices, achieving a breakthrough from 0 to 1 in research and development [3]. - The company is currently in the small-batch manufacturing phase, focusing on standardizing and modularizing its products to reduce production costs [3]. - Yuaneng Bio has successfully implemented its automated equipment in various projects, including those with the Chinese CDC and several hospitals [2]. Group 3: Future Outlook and Expansion - The company plans to enhance its global presence while deepening its domestic market engagement, with a focus on expanding its customer base internationally [3]. - Yuaneng Bio's Orcella Instruments brand won the "Outstanding New Product Award" at the ISBER awards in Canada, highlighting its international recognition [3]. - The company is set to complete a smart manufacturing base in Shanghai in 2024, covering nearly 10,000 square meters, to support its production capabilities [5].